Effect of alendronate on glucocorticoid-induced osteoporosis.
- Author:
Xiaoling ZOU
1
;
Qinxue LI
;
Chunhua SHI
Author Information
1. Department of Endocrinology, First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China.
- Publication Type:Clinical Trial
- MeSH:
Adult;
Alendronate;
therapeutic use;
Bone Density;
drug effects;
Bone Density Conservation Agents;
therapeutic use;
Female;
Humans;
Male;
Middle Aged;
Osteoporosis;
chemically induced;
drug therapy;
Prednisone;
adverse effects;
therapeutic use;
Rheumatic Fever;
drug therapy
- From:
Journal of Central South University(Medical Sciences)
2009;34(6):563-565
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the effect of alendronate on glucocorticoid-induced osteoporosis(GIO).
METHODS:Thirty-five GIO patients were enrolled. Ten milligrams alendronate were prescribed daily for 6 months. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometer (DEXA) after and before the treatment.
RESULTS:BMD at lumbar, neck and trochanter sites of the 35 patients after the treatment was significantly increased compared with those before the treatment (P<0.05). Urine Ca/Cr level was decreased (P<0.05). There was no severe side effect.
CONCLUSION:Alendronate is effective and well tolerated for GIO.
